EA200400464A1 - Способы и композиции новых триазиновых соединений - Google Patents

Способы и композиции новых триазиновых соединений

Info

Publication number
EA200400464A1
EA200400464A1 EA200400464A EA200400464A EA200400464A1 EA 200400464 A1 EA200400464 A1 EA 200400464A1 EA 200400464 A EA200400464 A EA 200400464A EA 200400464 A EA200400464 A EA 200400464A EA 200400464 A1 EA200400464 A1 EA 200400464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
compounds
inhibit
smooth muscle
methods
Prior art date
Application number
EA200400464A
Other languages
English (en)
Other versions
EA009728B1 (ru
Inventor
Ричард Т. Тиммер
Кристофер У. Эликзэндер
Сиварам Пилларисетти
Удэй Саксена
Карен А. Кемпбелл
Original Assignee
Редди Ю-Эс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редди Ю-Эс Терапьютикс, Инк. filed Critical Редди Ю-Эс Терапьютикс, Инк.
Publication of EA200400464A1 publication Critical patent/EA200400464A1/ru
Publication of EA009728B1 publication Critical patent/EA009728B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к способам и композициям, содержащим соединения, которые лечат физиологические состояния, возникающие из-за воспалительных ответов. В частности, настоящее изобретение направлено на соединения, которые ингибируют или блокируют вызываемую гликированным белком индукцию ассоциированного с передачей сигнала воспалительного ответа в эндотелиальных клетках. Настоящее изобретение относится к соединениям, которые ингибируют пролиферацию гладких мышц. В частности, настоящее изобретение направлено на соединения, которые ингибируют пролиферацию гладкомышечных клеток модуляцией гепарансульфатпротеогликанов, таких как перлекан. Настоящее изобретение далее относится к применению соединений для лечения сосудистых окклюзионных состояний, характеризующихся гладкомышечной пролиферацией, таких как рестеноз и атеросклероз.Отчет о международном поиске был опубликован 2003.12.11.
EA200400464A 2001-09-21 2002-09-23 Триазиновые соединения и их применение в медицине EA009728B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32414701P 2001-09-21 2001-09-21
PCT/US2002/030177 WO2003024926A2 (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Publications (2)

Publication Number Publication Date
EA200400464A1 true EA200400464A1 (ru) 2005-02-24
EA009728B1 EA009728B1 (ru) 2008-02-28

Family

ID=23262298

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400464A EA009728B1 (ru) 2001-09-21 2002-09-23 Триазиновые соединения и их применение в медицине

Country Status (16)

Country Link
EP (1) EP1436266A4 (ru)
JP (1) JP2005511509A (ru)
KR (1) KR20040088457A (ru)
CN (1) CN1578773A (ru)
BR (1) BR0212895A (ru)
CA (1) CA2461074A1 (ru)
EA (1) EA009728B1 (ru)
IL (1) IL160984A0 (ru)
IS (1) IS7190A (ru)
MX (1) MXPA04002680A (ru)
NO (1) NO20041187L (ru)
NZ (1) NZ532349A (ru)
PL (1) PL369600A1 (ru)
RS (1) RS34004A (ru)
WO (1) WO2003024926A2 (ru)
ZA (1) ZA200403009B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
ES2364645T3 (es) 2002-02-05 2011-09-08 Astellas Pharma Inc. Derivado de 2,4,6-triamino-1,3,5-triazina.
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
CA2533397A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CN1629157A (zh) * 2003-12-19 2005-06-22 中国科学院上海药物研究所 哌嗪三嗪类化合物、其制备方法及药物组合物
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
AU2007316217A1 (en) * 2006-11-03 2008-05-08 Nerviano Medical Sciences S.R.L. A method of administering an antitumor compound
KR101314869B1 (ko) * 2010-07-29 2013-10-04 광주과학기술원 트리아진계 화합물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 조성물
CN103347866B (zh) 2010-11-29 2016-05-18 加林制药公司 作为治疗呼吸控制不适或疾病的呼吸兴奋剂的新化合物
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
US10604492B2 (en) 2015-12-24 2020-03-31 The Regents Of The Universtiy Of California CFTR regulators and methods of use thereof
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083568C1 (ru) * 1994-05-05 1997-07-10 Кубанский государственный аграрный университет Соли триазинкарбоновых кислот и средство для предпосевной обработки семян сельскохозяйственных культур
DE19531084A1 (de) * 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JP2002542144A (ja) * 1997-12-12 2002-12-10 アボット・ラボラトリーズ トリアジン系血管形成阻害剤
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof

Also Published As

Publication number Publication date
IS7190A (is) 2004-03-19
ZA200403009B (en) 2007-12-27
JP2005511509A (ja) 2005-04-28
EP1436266A2 (en) 2004-07-14
PL369600A1 (en) 2005-05-02
MXPA04002680A (es) 2004-06-18
BR0212895A (pt) 2005-05-10
IL160984A0 (en) 2004-08-31
CA2461074A1 (en) 2003-03-27
EP1436266A4 (en) 2004-12-22
RS34004A (en) 2006-10-27
WO2003024926A3 (en) 2003-12-11
KR20040088457A (ko) 2004-10-16
NZ532349A (en) 2007-02-23
WO2003024926A2 (en) 2003-03-27
NO20041187L (no) 2004-05-19
CN1578773A (zh) 2005-02-09
EA009728B1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
EA200400464A1 (ru) Способы и композиции новых триазиновых соединений
EA200500249A1 (ru) Применение соединений для лечения заболевания, опосредованного vcam-1
ATE450515T1 (de) Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren
PT1362047E (pt) Compostos de pirrolina substituidos com indazolilo como inibidores de cinase
NZ335981A (en) Ketobenzamides as calpain inhibitors
BR0314670A (pt) Métodos e composições de compostos de triazina
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
ATE273273T1 (de) Phenylalaninderivate als inhibitoren von alpha4 integrinen
ATE192045T1 (de) Verwendung von substituierten adeninderivaten zur behandlung von multiplesklerose
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
EA200100965A1 (ru) Синергизм между низкомолекулярным гепарином и ингибиторами агрегации тромбоцитов, обеспечивающий комбинированную терапию для профилактики и лечения различных тромбоэмболических нарушений
FR2780729B1 (fr) Derives zwitterioniques et application aux proprietes des suspensions aqueuses
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
EA200300066A1 (ru) Производные аминоалкоксибензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции
NO976112L (no) 1,6-disubstituerte isokromaner for behandling av migrene
ATE184604T1 (de) Neue 2-substituierte tricyclische derivate von indan-2-mercaptoacetylamid verwendbar als enkephalinase inhibitoren
EA200200948A1 (ru) Лечение псориаза
DE59403966D1 (de) Hydroxymethylfurazancarbonsäurederivate und ihre verwendung in der behandlung von kardiovaskulären erkrankungen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
PT758890E (pt) Utilizacao de agentes de captura, inibidores ou antagonistas de no no tratamento da enxaqueca

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU